
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

Date of Report: June 29, 2023

Commission File Number: 001-36891

Collectis S.A.

(Exact Name of registrant as specified in its charter)

**8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

General Meeting

Cellectis S.A. (the “Company”) held its Combined Ordinary and Extraordinary General Meeting (the “Meeting”) on June 27, 2023. Filed as Exhibits 99.1 and 99.2 hereto are the press release and the voting results for the Meeting, respectively.

Board of Directors Update

On June 27, 2023, Mrs. Cécile Chartier has been appointed as director of the Company’s board of director. The terms of office of Mr. Hervé Hoppenot and Mrs. Annick Schwebig ended just after the June 27, 2023 Meeting.

EXHIBIT INDEX

<u>Exhibit</u>	<u>Title</u>
99.1	Press Release, dated June 28, 2023
99.2	Voting Results for the Combined Ordinary and Extraordinary General Meeting

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELLECTIS S.A.
(Registrant)

June 29, 2023

By: /s/ André Choulika
André Choulika
Chief Executive Officer



PRESS RELEASE

Collectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 27, 2023

June 28, 2023 – New York (N.Y.) – Collectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

At the meeting, during which more than 72% of shares were exercised, Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations.

The detailed results of the vote and the resolutions are available on the company's website: <https://www.collectis.com/en/investors/general-meetings/>

About Collectis

Collectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Collectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 23 years of experience and expertise in gene editing, Collectis is developing life-changing product candidates utilizing TALEN[®], its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Collectis' headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Collectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit our website www.collectis.com

Follow Collectis on social media: @collectis, LinkedIn and YouTube

For further information on Collectis, please contact:

Media contact:

Pascaline Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@collectis.com

Investor Relation contact:

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@collectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 27, 2023

VOTE RESULTS

Ordinary Resolutions

NB	Resolution	Result	For		Against		Vote withhold		Total votes	Shares represented by the votes cast	Percentage of the share capital represented by the votes cast	Out of vote voting rights	Null voting rights	Quorum
			Votes	%	Votes	%	Votes	%						
1	Approval of the annual financial statements for the financial year ended December 31, 2022													
	1	Carried	44 957 162	99.48%	233 303	0.52%	27 732	—	45 190 465	40 379 160	72.645%	0	0	72.645%
2	Approval of the consolidated financial statements for the financial year ended December 31, 2022													
	2	Carried	44 957 137	99.48%	233 303	0.52%	27 757	—	45 190 440	40 379 160	72.645%	0	0	72.645%
3	Appropriation of results for the financial year ended December 31, 2022													
	3	Carried	44 926 569	99.41%	265 543	0.59%	26 085	—	45 192 112	40 379 160	72.645%	0	0	72.645%
4	Allocation of losses carried forward to the “share premium” account													
	4	Carried	44 957 932	99.48%	233 808	0.52%	26 457	—	45 191 740	40 379 160	72.645%	0	0	72.645%
5	Review of the agreements considered in articles L. 225-38 et seq. of the Commercial Code													
	5	Carried	38 406 039	99.39%	233 938	0.61%	12 433	—	38 639 977	36 692 873	66,013%	6 565 787	0	72.645%
6	Renewal of the appointment of Mr. Jean-Pierre Garnier													
	6	Carried	42 038 335	93.00%	3 164 379	7.00%	15 483	—	45 202 714	40 379 160	72.645%	0	0	72.645%

VOTE RESULTS

Ordinary Resolutions

NB	Resolution	Result	For		Against		Vote withhold		Total votes	Shares represented by the votes cast	Percentage of the share capital represented by the votes cast	Out of vote voting rights	Null voting rights	Quorum
			Votes	%	Votes	%	Votes	%						
7	Renewal of the appointment of Mr. Laurent Arthaud													
	7	Carried	43 046 342	95.23%	2 156 396	4.77%	15 459	—	45 202 738	40 379 160	72.645%	0	0	72.645%
8	Renewal of the appointment of Mr. Pierre Bastid													
	8	Carried	40 673 751	92.94%	3 091 670	7.06%	15 483	—	43 765 421	38 941 867	70.059%	1 437 293	0	71.91%
9	Renewal of the appointment of Mr. Rainer Boehm													
	9	Carried	42 089 019	93.11%	3 113 719	6.89%	15 459	—	45 202 738	40 379 160	72.645%	0	0	72.645%
10	Appointment of a new director (Mrs Cecile Chartier)													
	10	Carried	44 937 320	99.41%	268 730	0.59%	12 147	—	45 206 050	40 379 160	72.645%	0	0	72.645%
11	Authorization to the Board of Directors to buy back shares of the Company													
	11	Carried	44 678 742	98.84%	526 086	1.16%	13 369	—	45 204 828	40 379 160	72.645%	0	0	72.645%

VOTE RESULTS

Extraordinary Resolutions

NB	Resolution	Result	For		Against		Vote withhold		Total votes	Shares represented by the votes cast	Percentage of the share capital represented by the votes cast	Out of vote voting rights	Null voting rights	Quorum
			Votes	%	Votes	%	Votes	%						
12	Authorization to be granted to the Board of Directors to reduce the share capital by cancelling shares under the authorization to buy back its own shares	12 Carried	44 880 463	99.28%	324 279	0.72%	13 455	—	45 204 742	40 379 160	72.645%	0	0	72.64%
13	Amendment of the age limit applicable to the chairman of the Board of Directors – subsequent amendment of the articles of association	13 Carried	38 295 611	84.72%	6 907 819	15.28%	14 767	—	45 203 430	40 379 160	72.645%	0	0	72.64%
14	Delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with cancellation of shareholders' preferential subscription rights in favor of the European Investment Bank (EIB) or of other entities that may succeed EIB, according to any finance agreement entered or be entered with EIB	14 Carried	44 812 227	99.13%	393 537	0.87%	12 433	—	45 205 764	40 379 160	72.645%	0	0	72.64%
15	Delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with cancellation of shareholders' preferential subscription rights in favor of a category of persons meeting specified characteristics (investors with experience in the health or biotech sector)	15 Carried	44 588 540	98.63%	617 502	1.37%	12 155	—	45 206 042	40 379 160	72.645%	0	0	72.64%
16	Delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with cancellation of shareholders' preferential subscription rights in favor of a category of persons meeting specified characteristics (e.g. credit institution, investment services provider or member of an investment pool guaranteeing the completion of the issue in question), including, as the case may, within the framework of an equity financing program known as "At-the-market" or "ATM"	16 Carried	44 570 910	98.60%	635 132	1.40%	12 155	—	45 206 042	40 379 160	72.645%	0	0	72.64%
17	Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares or any other securities, with cancellation of shareholders' preferential subscription rights in favor of a category of persons meeting specified characteristics (industrial companies, institutions or entities active in the health or biotechnology sector)	17 Carried	44 602 515	98.66%	603 527	1.34%	12 155	—	45 206 042	40 379 160	72.645%	0	0	72.64%

VOTE RESULTS

Extraordinary Resolutions

NB	Resolution	Result	For		Against		Vote withhold		Total votes	Shares represented by the votes cast	Percentage of the share capital represented by the votes cast	Out of vote voting rights	Null voting rights	Quorum
			Votes	%	Votes	%	Votes	%						
18	Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares or any other securities with cancellation of shareholders' preferential subscription rights in favor of a category of persons meeting specified characteristics in the framework of an equity or bond financing agreement	18 Carried	44 602 475	98.66%	603 567	1.34%	12 155	—	45 206 042	40 379 160	72.645%	0	0	72.645%
19	Delegation of authority to be granted to the Board of Directors to decide on the issuance of ordinary shares to be issued immediately or in the future by the Company, with cancellation of the shareholders' preferential subscription rights, to the benefit of a category of persons meeting specified characteristics within the framework of an equity financing program on the American market known as "At-the-market" or "ATM"	19 Carried	44 602 475	98.66%	603 567	1.34%	12 155	—	45 206 042	40 379 160	72.645%	0	0	72.645%
20	Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares and/or any other securities, with the shareholders' preferential subscription rights maintained	20 Carried	44 869 970	99.26%	336 332	0.74%	11 895	—	45 206 302	40 379 160	72.645%	0	0	72.645%
21	Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares and/or any other securities, with cancellation of shareholders' preferential subscription rights, by way of a public offering (other than the offerings referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code)	21 Carried	44 556 890	98.56%	649 412	1.44%	11 895	—	45 206 302	40 379 160	72.645%	0	0	72.645%
22	Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares and/or any other securities, with cancellation of the shareholders' preferential subscription rights in the context of an offer referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code	22 Carried	44 602 475	98.66%	603 827	1.34%	11 895	—	45 206 302	40 379 160	72.645%	0	0	72.645%
23	Delegation to the Board of Directors to increase the number of shares to be issued in the event of a capital increase with or without preferential subscription rights	23 Carried	44 682 772	98.84%	523 530	1.16%	11 895	—	45 206 302	40 379 160	72.645%	0	0	72.645%

VOTE RESULTS

Extraordinary Resolutions

NB	Resolution	Result	For		Against		Vote withhold		Total votes	Shares represented by the votes cast	Percentage of the share capital represented by the votes cast	Out of vote voting rights	Null voting rights	Quor	
			Votes	%	Votes	%	Votes	%							
24	Overall limitations on the amount of issues made under the Fifteenth resolution to the Twenty-third resolution aforementioned	24	Carried	44 957 035	99.45%	248 989	0.55%	12 173	—	45 206 024	40 379 160	72.645%	0	0	72.6
25	Delegation of authority granted to the Board of Directors to increase the capital by incorporation of premiums, reserves, profits or other	25	Carried	44 949 687	99.43%	256 337	0.57%	12 173	—	45 206 024	40 379 160	72.645%	0	0	72.6
26	Authorization to the Board of Directors to grant options to subscribe for or purchase shares of the Company	26	Carried	43 511 983	96.25%	1 693 781	3.75%	12 433	—	45 205 764	40 379 160	72.645%	0	0	72.6
27	Authorization to the Board of Directors to proceed with the free allocation of existing and/or new ordinary shares	27	Carried	43 701 908	96.67%	1 503 856	3.33%	12 433	—	45 205 764	40 379 160	72.645%	0	0	72.6
28	Overall limits on the amount of issues made under the above issues made under the Twenty-sixth and the Twenty-seventh resolution above	28	Carried	44 959 774	99.46%	246 269	0.54%	12 154	—	45 206 043	40 379 160	72.645%	0	0	72.6
29	Delegation to the Board of Directors to proceed with an increase in the share capital, the subscription of which would be reserved for the members of a company savings plan established pursuant to Articles L. 3332-1 et seq. of the Labor Code	29	Rejected	5 796 401	12.83%	39 396 224	87.17%	25 572	—	45 192 625	40 379 160	72.645%	0	0	72.6